Beta Bionics Announces Near Real-Time Real-World Data On iLet Bionic Pancreas Is Now Publicly Available At betabionics.com/hcp/real-world-data

Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that near real-time real-world data on the iLet Bionic Pancreas is now publicly available at betabionics.com/hcp/real-world-data. The dashboard publishes outcomes for 100% of the iLet patients who meet two simple, pre-stated criteria (a provider-reported baseline HbA1c and at least two weeks of data uploaded to the cloud), with no exclusions applied.

Real-world data is a key reference point for clinicians weighing multiple automated insulin delivery (AID) options. Most of the evidence in the category arrives in batches: posters, abstracts, paragraphs in earnings releases. Beta Bionics is taking a different approach. The data is published continuously and openly, available to anyone who wants to evaluate the iLet on its real-world performance, including clinicians, researchers, payers, patients, and the broader diabetes community.